How India Exports Diagnostic to the World

The U.S. Food and Drug Administration (FDA) maintains the Orange Book, a comprehensive resource listing approved drug products, including those under Abbreviated New Drug Applications (ANDAs). The Orange Book is updated daily to reflect new generic drug approvals, ensuring stakeholders have access to current information.

For products classified under HS Code 30029010, which encompasses various diagnostic agents, the FDA's regulatory pathway involves rigorous evaluation to ensure safety and efficacy. Manufacturers seeking to market these products in the U.S. must submit an ANDA, demonstrating bioequivalence to a reference listed drug (RLD). The FDA's Orange Book provides detailed information on approved drug products, including their therapeutic equivalence evaluations.

Given the substantial number of active Indian exporters—99 companies exporting to 123 countries—the U.S. market presents a significant opportunity. However, compliance with FDA regulations, including adherence to Good Manufacturing Practices (GMP) and accurate product labeling, is imperative to ensure market access and maintain product integrity.

In the European Union (EU), the European Medicines Agency (EMA) oversees the approval and regulation of medicinal products, including diagnostic agents. Manufacturers must obtain a marketing authorization, which requires comprehensive data on product quality, safety, and efficacy. The EU's Good Manufacturing Practice (GMP) guidelines ensure that products are consistently produced and controlled according to quality standards.

In the United Kingdom (UK), the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medicines and medical devices. Post-Brexit, the UK has established its own regulatory framework, though it closely aligns with EU standards. Manufacturers exporting to the UK must comply with MHRA requirements, including obtaining the necessary marketing authorizations and adhering to GMP standards.

The World Health Organization (WHO) maintains the Model List of Essential Medicines, identifying medications considered essential for basic healthcare systems. Inclusion in this list signifies a product's importance in addressing public health needs. Additionally, the WHO Prequalification Programme assesses the quality, safety, and efficacy of medicinal products, facilitating their procurement by UN agencies and member states.

Diagnostic agents must comply with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures product quality and facilitates international trade by harmonizing specifications across different regions.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies drugs into various schedules under the Drugs and Cosmetics Act. Diagnostic agents may fall under Schedule H, H1, or X, depending on their composition and intended use. These classifications dictate prescription requirements and control measures to ensure safe usage.

The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of pharmaceutical products to ensure affordability. Manufacturers must comply with the Drug Price Control Order (DPCO) provisions, which may impose ceiling prices on certain diagnostic agents. Additionally, the Directorate General of Foreign Trade (DGFT) mandates that exporters obtain a No Objection Certificate (NOC) for specific pharmaceutical products, ensuring compliance with export regulations.

Patent protection for diagnostic agents under HS Code 30029010 varies based on the specific product and its formulation. The FDA's Orange Book lists patents associated with approved drug products, providing transparency on exclusivity periods. Once patents expire, generic competition typically increases, leading to more affordable options in the market. Manufacturers must monitor patent statuses to strategize market entry and navigate potential exclusivity challenges.

In May 2025, the FDA released draft guidance titled "Replacing Color Additives in Approved or Marketed Drug Products," addressing the process for modifying color additives in existing products. This guidance aims to streamline regulatory submissions for such changes, impacting manufacturers of diagnostic agents seeking to update formulations.

In January 2026, the FDA updated the Orange Book to enhance clarity on reference listed drugs (RLDs) and reference standards. These updates assist ANDA applicants in accurately identifying appropriate RLDs and reference standards, facilitating the approval process for generic diagnostic agents.

In January 2026, the Congressional Research Service published a report titled "Patent Listing in FDA’s Orange Book," providing an overview of the patent listing process and its implications for generic drug competition. This report offers valuable insights for manufacturers navigating patent landscapes in the diagnostic sector.

In February 2026, the FDA emphasized the importance of the one-time marketing status report required by the FDA Reauthorization Act of 2017 (FDARA). This report mandates that NDA and ANDA holders confirm the marketing status of their approved products, ensuring the accuracy of the Orange Book listings.

In March 2026, the FDA announced the availability of the latest Orange Book data files, providing updated information on approved drug products, including therapeutic equivalence evaluations. These resources are essential for stakeholders in the diagnostic industry to stay informed about market dynamics and regulatory statuses.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's API requirements are fulfilled by Chinese suppliers. This dependency exposes the supply chain to significant risks, as any disruption in Chinese production or export policies can lead to shortages and price volatility in the Indian pharmaceutical sector.

The COVID-19 pandemic underscored these vulnerabilities when Chinese factory shutdowns led to immediate scarcities of essential APIs, causing price surges for common medications. Recognizing this, the Indian government initiated the Production Linked Incentive (PLI) scheme in October 2024 to bolster domestic API and KSM manufacturing. Two greenfield plants were inaugurated under this scheme, aiming to produce critical molecules like Penicillin G and 6-Aminopenicillanic acid (6-APA), which are vital for antibiotic production.

Our proprietary trade data indicates a high supplier concentration in the export of diagnostic products from India. The top five exporters account for 72.1% of total exports, with ADVY CHEMICAL PRIVATE LIMITED alone contributing 37.4%. Such concentration poses a single-source risk; any operational or compliance issues within these key suppliers could disrupt the entire supply chain.

The PLI scheme, launched in October 2024, aims to mitigate these risks by incentivizing domestic production of APIs and KSMs. While this initiative is a positive step, its success depends on timely implementation and the ability of new manufacturers to meet quality standards and production targets.

Recent geopolitical tensions have further strained the pharmaceutical supply chain. In February 2026, the closure of the Strait of Hormuz disrupted the movement of oil and other critical goods, including pharmaceuticals. This blockade led to increased shipping costs and delays, affecting the timely delivery of raw materials and finished products. Additionally, the ongoing Iran war has caused significant disruptions in global supply chains, impacting the distribution of pharmaceuticals from India.

The U.S. Food and Drug Administration (FDA) has been actively monitoring these disruptions. In April 2024, the U.S. Department of Health and Human Services released a white paper highlighting steps taken to prevent and mitigate drug shortages, emphasizing the need for a resilient supply chain.

• Diversify Supplier Base: Encourage the development of multiple domestic suppliers for critical APIs and KSMs to reduce dependency on a single source.

• Strengthen Domestic Manufacturing: Accelerate the implementation of the PLI scheme and provide support to new entrants to ensure they meet production and quality standards.

• Enhance Supply Chain Visibility: Implement advanced tracking systems to monitor the movement of raw materials and finished products, allowing for proactive responses to potential disruptions.

• Develop Strategic Reserves: Establish reserves of essential APIs and KSMs to buffer against short-term supply chain disruptions.

• Engage in International Collaboration: Work with global regulatory bodies and trade partners to develop contingency plans for geopolitical events that may impact the pharmaceutical supply chain.

RISK_LEVEL: HIGH